CASTLE ROCK, Colo., Feb. 11, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that its presentation at the 2013 BIO CEO and Investor Conference, to be held February 11-12, 2013, at the Waldorf Astoria Hotel in New York, has been rescheduled for Tuesday, February 12, 2013.
Steve Lundy , President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Event:BIO CEO and Investor ConferenceDate: Tuesday, February 12, 2013 Time: 10:00 am (Eastern Time) Location:Astor Room, 3rd Floor; Waldorf Astoria Hotel; New YorkThe presentation will be webcast live. To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast replay will remain available for 90 days.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1. The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.
|SOURCE Venaxis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved